Skip to content

Study · Case report or series · n = 1 · 2024

1 result

Tendency of Semaglutide to Induce Gastroparesis: A Case Report.

Chaudhry A, Gabriel B, Noor J, Jawad S, Challa SR

Cureus19 Jan 2024Cited by 19 (Europe PMC)

PMID38371020 (opens in a new tab)PMCIDPMC10874596 (opens in a new tab)DOI10.7759/cureus.52564 (opens in a new tab)PepBankPUB-38371020
Download PDFPubMedAsk about this study
Jump to 1 result

Summary

Semaglutide, an agonist of the glucagon-like peptide-1 receptor, is frequently used in the treatment of diabetes mellitus type 2, although, lately, weight loss has additionally become a reason for its use. However, if a patient is already experiencing bloating, nausea, abdominal pain, and discomfort in the abdomen, it is not recommended to use it due to concern about aggravating these symptoms. Although it is often well tolerated, there are occasions when it can have several gastrointestinal side effects. Therefore, we report a case of a patient who started taking semaglutide and later developed gastroparoresis.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesSafety outcome

    In one patient, gastroparesis developed after the patient started taking semaglutide.

    In plain wordsOne patient developed gastroparesis after starting semaglutide. A single case cannot show that semaglutide caused it.

    Peptide
    Semaglutide
    Outcome
    IncreaseGastroparesis
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Therefore, we report a case of a patient who started taking semaglutide and later developed gastroparoresis.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.